<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBiSE</journal-id><journal-title-group><journal-title>Journal of Biomedical Science and Engineering</journal-title></journal-title-group><issn pub-type="epub">1937-6871</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbise.2013.63A041</article-id><article-id pub-id-type="publisher-id">JBiSE-29484</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Lesion contrast differences in MRI sequences in multiple sclerosis: Correlation to clinical disability
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>aija</surname><given-names>Rossi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Minna</surname><given-names>Raunio</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pertti</surname><given-names>Ryymin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Irina</surname><given-names>Elovaara</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Prasun</surname><given-names>Dastidar</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Medical Imaging Centre, Department of Radiology, Tampere University Hospital, Tampere, Finland</addr-line></aff><aff id="aff3"><addr-line>Tampere Medical School, Tampere, Finland</addr-line></aff><aff id="aff2"><addr-line>Department of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>maija.rossi@pshp.fi(AR)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>03</month><year>2013</year></pub-date><volume>06</volume><issue>03</issue><fpage>319</fpage><lpage>326</lpage><history><date date-type="received"><day>11</day>	<month>December</month>	<year>2012</year></date><date date-type="rev-recd"><day>13</day>	<month>January</month>	<year>2013</year>	</date><date date-type="accepted"><day>21</day>	<month>January</month>	<year>2013</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   The purpose of this study was to analyze the lesion brightness (image contrast) in multiple MRI sequences in patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and clinically isolated syndrome (CIS); and to correlate the lesion contrast with lesion volumes and neurological disability. MRI ex- amination at 1.5 T was performed on 80 patients with RRMS, SPMS, PPMS, or CIS. The protocol included T<sub>1</sub>- and T<sub>2</sub>-weighted spin echo (SE), fluid attenuated inversion recovery (FLAIR), T<sub>1</sub>-weighted SE with magnetization transfer preparation, and diffusion weighted imaging (DWI). Contrast was measured between MS lesions and normal appearing white matter. Lesion volume was calculated in T<sub>1</sub>-weighted- and FLAIR-images. All patients were examined neurologically including evaluation of expanded disability status scale (EDSS) score. Lesion contrast correlated with total brain lesion volume (p = 0.000 - 0.040). In patients with low EDSS, three sequences were able to differentiate between CIS and RRMS. SPMS and PPMS were separated by DWI. Lesion contrast correlated with EDSS score on T<sub>1</sub>-weighted imaging, with or without magnetization transfer preparation. Patient age correlated with lesion contrasts. Contrast measurements seem limited in radiological and clinical diagnosis of MS in reference to disease course, its activity and progression. The differentiation between MS subgroups might improve at 3 T and could help in leading to earlier treatment of the disease.  
 
</p></abstract><kwd-group><kwd>Magnetic Resonance Imaging; Multiple Sclerosis; Imaging Sequences</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. INTRODUCTION</title><p>Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and it is characterized by complex pathophysiological processes including inflammation, demyelination, axonal loss, and remyelination [<xref ref-type="bibr" rid="scirp.29484-ref1">1</xref>].<sup> </sup>MS lesions are commonly seen in the cerebral hemispheres, brain stem, and cervical part of spinal cords myelin. The initial onset of symptoms usually occurs between 20 - 40 years of age.</p><p>The disease develops gradually, and symptoms often present with seemingly unrelated timing and distribution. MS can be divided into different stages. In clinically isolated syndrome (CIS), the patient does not fulfill the international criteria for MS, i.e., the revised McDonald criteria [1-3], but 30% - 70% of these patients develop MS later on [<xref ref-type="bibr" rid="scirp.29484-ref4">4</xref>]. In relapsing-remitting MS (RRMS), there are phases of rapid disease progression, but the inflammation is reversible and is followed by periods of neurological improvement without development of new symptoms. RRMS usually progresses into secondary progressive MS (SPMS), characterized by gradual increase of neurological disability without clinical relapses. In some patients, the disease course continually progresses from the beginning, and is referred to as primary progressive MS (PPMS). These patients have a worse prognosis than in RRMS. The neurological disability of MS is evaluated by expanded disability status scale (EDSS).</p><p>Radiologically, MS is imaged using a variety of magnetic resonance imaging (MRI) sequences. More lesions can be detected at 3 Tesla (T) than at 1.5 T [5,6]. However, 1.5 T is more commonly available than 3 T. Consequently, imaging is usually performed on 1.5-T scanners. The MRI protocol for MS patients usually includes T<sub>1</sub>- and T<sub>2</sub>-weighted spin echo (SE), the former of which can be performed three-dimensionally [<xref ref-type="bibr" rid="scirp.29484-ref7">7</xref>], fluid attenuated inversion recovery (FLAIR), and occasionally, T<sub>1</sub>- weighted imaging with magnetization transfer (MT) preparation. Since the last decade the protocol is increasingly accompanied by diffusion weighted imaging (DWI) [8,9].</p><p>Several studies have investigated various MRI characteristics of MS patients. These studies have revealed tissue alterations, such as changes in both normal appearing brain tissue and lesions, in magnetization transfer ratio (MTR) [10,11]. In addition, abnormal brain iron deposits in the putamen and thalamus have been measured as T<sub>2</sub> decrease [12-16] or phase development [17,18]. Studies of the most conventional imaging sequences, i.e., T<sub>1</sub>- and T<sub>2</sub>-weighted SE, have mainly focused on number of lesions and lesion volume, along with brain atrophy [19- 23]. Also the use of a composite score of MRI measures has been proposed [<xref ref-type="bibr" rid="scirp.29484-ref24">24</xref>]. Although semi-automatic software has been developed to assess volume information [25-27], volumetric measurements are time-consuming and, therefore, a poor fit for clinical environment.</p><p>Easily accessible parameters, such as a rapid measurement of signal intensity, S, and calculation of lesion contrast, <img src="3-9101577\88f55f7e-b015-4680-818a-9cea111bef29.jpg" />, where S<sub>a</sub> and S<sub>b</sub> are the signal intensities of structures a and b, respectively, are better suited for clinical purposes, as long as they provide pertinent information about the disease. Interest in this type of measurement was first seen in the late 1990s [28-30]. Contrast was measured on film and the results were supported with biopsy or post-mortem studies. MTR and the degree of hypointensity in T<sub>1</sub>-weighted images were shown to correlate with axonal density. However, no recent reports with digital MR images are available.</p><p>The purpose of this study is to compare multiple standardized MR imaging sequences and investigate the relationship between lesion contrast attributes, volumes, and clinical characteristics of the patients.</p></sec><sec id="s2"><title>2. PATIENTS AND METHODS</title><p>This study included 98 patients with three different subtypes of MS and CIS. All patients underwent thorough neurological examination, including evaluation of EDSS score. The neurological evaluation was performed by the same experienced neurologist (M. Ra.), and the diagnosis was based on the revised McDonald criteria [<xref ref-type="bibr" rid="scirp.29484-ref3">3</xref>]. The patients did not have active lesions at the time of imaging. Each of the four subgroups (CIS, RRMS, SPMS, PPMS) had a minimum of 20 patients and thus, for this paper we included 20 patients of each subgroup. Within subgroups where more patients were available, the most recent patients were selected. These 80 patients (male: female = 23:57, age range 18 - 73 years, mean age 45 years) underwent MRI examination. Main patient characteristics are presented in <xref ref-type="table" rid="table1">Table 1</xref>. Age is listed at the time of imaging. The study was approved by the Hospital Ethics Committee, and all patients gave written informed consent.</p><sec id="s2_1"><title>2.1. MRI Protocol</title><p>Imaging was performed with a 1.5 T MRI unit (Siemens Avanto, Erlangen, Germany). Imaging parameters are presented in <xref ref-type="table" rid="table2">Table 2</xref>. Due to limitations in specific absorption rate (SAR), slight modifications had to be made in a few patients concerning repetition time (TR) and echo time (TE). T<sub>1</sub>-weighted MP-RAGE was acquired once without, and once with the intravenous contrast agent gadoterate meglumine (Gd-DODA; Dotarem<sup>&#174;</sup> 10 ml). In T<sub>2</sub>-weighted SE, time savings were accomplished using fast recovery mode which uses spoiler gradients at the end of the relatively short TR period. For scientific studies on MS patients, the MTR is often calculated; this measurement, however, requires acquisition of two image sets, one with and one without the off-frequency preparatory pulse. Due to time limitations in clinical environments, in this study we wanted to see if T<sub>1</sub>-weighted imaging with MT preparation alone, omitting the sequence without off-frequency pulse, correlates with clinical data.</p></sec><sec id="s2_2"><title>2.2. ROI Localization</title><p>In each patient, two MS lesions were selected for signal</p><p><xref ref-type="table" rid="table1">Table 1</xref>. Patient characteristics. Median (and range) values given.</p><p><img src="3-9101577\2f90dac2-ff0b-4188-90d9-eaf8e1355a8d.jpg" /></p><p>CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS; PPMS = primary progressive MS; EDSS = expanded disability status scale.</p><p><xref ref-type="table" rid="table2">Table 2</xref>. Typical imaging parameters.</p><p><img src="3-9101577\d6819012-8d3a-40aa-a519-714bdd9b9efa.jpg" /></p><p>DWI = diffusion-weighted imaging; FR = fast recovery; EPI = echo planar imaging; (T) SE = (turbo) spin echo; FLAIR = fluid attenuated inversion recovery; IR = inversion recovery; MT = magnetization transfer; MP-RAGE = magnetization prepared rapid acquisition gradient echo; GRE = gradient echo.</p><p>analysis: one in the cerebral hemisphere and one in the infratentorial compartment of the brain. The largest lesions, shown most clearly in each imaging sequence, were selected. All images were analyzed by the same person (M.Ro.) under the supervision of an experienced neuroradiologist (P.D.).</p><p>For each lesion, the signal intensity was measured in three regions of interest (ROI) within the same slice: 1) within the lesion, 2) in adjacent normal appearing white matter (NAWM) next to the lesion, and 3) in the lesioncorresponding contralateral NAWM region (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Whenever possible, lesions with a corresponding lesionfree region in the contralateral hemisphere were selected; if this was not possible, slight divergence from the corresponding contralateral region was permitted to identify an area of normal-appearing tissue. In all contralateral NAWM ROIs (3), there were no MS lesions within 15 mm of the ROI. Although patients with CIS did not fulfill the revised McDonald criteria for MS disease of nine detectable lesions, all CIS patients included in this study did have at least one or two detectable lesions in the cerebral hemispheres and infratentorial compartment of brain.</p></sec><sec id="s2_3"><title>2.3. Analysis Methods</title><p>Due to the non-quantitative nature of the MRI sequences, direct comparisons of the signal intensities among individuals were not conducted. This type of comparison likely would have led to an error due to variations in not only from examination to examination and patient to patient, but also in the same examination from slice to slice. Instead, we analyzed contrast,</p><p><img src="3-9101577\0fab65a7-f85c-45af-bed7-939c95ec1569.jpg" />,</p><p>where S<sub>a</sub> and S<sub>b</sub> are the signal intensities of regions a and b, respectively, within the same slice. Although contrast is conventionally measured between two adjacent tissues, we also made comparisons to the contralateral hemisphere.</p><p>Total lesion volume was measured in T<sub>2</sub>-weighted FLAIR and T<sub>1</sub>-weighted SE images, and brain atrophy in T<sub>2</sub>-weighted SE images, using an enhanced version of the calibrated semi-automatic segmentation software Anatomatic<sup>TM</sup> 2.23 [18,24,31,32].</p><p>Normality of distributions was analyzed according to Kolmogorov-Smirnov test. Comparisons between MS subgroups were analyzed with ANOVA tests. Correlations between contrast and each brain atrophy, age, and disease duration were calculated using Pearson’s correlation. Due to skewed distributions, shown by the Kolmogorov-Smirnov test, correlations between contrast and both lesion volume and EDSS scores were calculated using Spearman’s rho correlation. Comparisons between MRI sequences were performed with student’s paired t-test or, in case of non-Gaussian contrast distribution within the patient group, with Wilcoxon signed ranks test. All statistical calculations were computed with SPSS 17 (SPSS Inc., Chicago, Illinois, USA). P-values of less than 0.05 were considered statistically significant for n = 80 and p-values less than 0.01 for n = 20.</p></sec></sec><sec id="s3"><title>3. RESULTS</title><sec id="s3_1"><title>3.1. MRI Contrast and Lesion Volume</title><p>Lesion contrast was slightly correlated with both T<sub>1</sub>- weighted and FLAIR lesion volume (<xref ref-type="table" rid="table3">Table 3</xref>). Brain atrophy was not correlated with MRI-given lesion contrast.</p></sec><sec id="s3_2"><title>3.2. MRI Contrast and Clinical Characteristics</title><p>MS lesion contrast to NAWM is presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>. SPMS patients had larger lesion contrast than RRMS patients in T<sub>1</sub>-weighted MP-RAGE in the cerebral hemisphere (p = 0.040). In the infratentorial compartment of the brain the difference was significant in FLAIR (p = 0.017) between CIS and SPMS. We also grouped patients by their EDSS scores with 0 - 1.5, 2 - 4, and 5 - 8. Differentiation between RRMS and SPMS was found in patients with EDSS score between 2 and 4 (DWI: p = 0.029, T<sub>1</sub>-weighted MP-RAGE: p = 0.042).</p><p>In the cerebral hemisphere, MRI contrast correlated with EDSS scores (p &lt; 0.01) in the total patient population in all three sequences using T<sub>1</sub>-weighted imaging: in MT-prepared T<sub>1</sub>-weighted imaging (r = −0.288), and T<sub>1</sub>- weighted MP-RAGE without (r = −0.315) and with (r =</p><p><xref ref-type="table" rid="table3">Table 3</xref>. Correlation between lesion contrast and total lesion volume. Spearman’s rho and (p-value).</p><p><img src="3-9101577\1c31b245-887d-4cfb-b571-5c906d1b725b.jpg" /></p><p>DWI = diffusion-weighted imaging; MT = magnetization transfer; T<sub>1(2)</sub>W = T<sub>1(2)</sub>-weighted image; FLAIR = fluid-attenuated inversion recovery; C = contrast agent.</p><p>−0.342) contrast agent. In the subgroups of MS, there were no correlations. In the infratentorial compartment of the brain, the EDSS score correlation with lesion contrast was modest with tendencies to correlate (p &lt; 0.05) in T<sub>2</sub>-weighted SE (r = 0.472) and T<sub>1</sub>-weighted MPRAGE (r = −0.450) in the RRMS subgroup. Generally, the tendency was towards larger lesion contrast with higher EDSS score.</p></sec><sec id="s3_3"><title>3.3. MRI Contrast and Patient Age</title><p>Patient age correlated with the MRI contrast between MS lesion and both adjacent and contralateral NAWM. Older patients had higher lesion contrast in the cerebral hemispheres in CIS (p &lt; 0.05, in DWI: r = 0.495, T<sub>2</sub>-weighted SE: r = 0.560, T<sub>1</sub>-weighted MP-RAGE: r = −0.453) and SPMS patients (p &lt; 0.05, in DWI r = 0.462); and in the infratentorial compartment in CIS patients (p &lt; 0.05, in T<sub>1</sub>-weighted MP-RAGE r = −0.527). However, in the infratentorial compartment of brain reverse correlation was seen in PPMS patients (T<sub>1</sub>-weighted MT, MP-RAGE and T<sub>2</sub>-weighted SE p &lt; 0.01). Similar correlation was measured in the lesion contrast contralateral NAWM.</p></sec></sec><sec id="s4"><title>4. DISCUSSION</title><p>The immune-mediated MS disease is primarily characterized by inflammation and demyelination, followed by neurodegeneration, including axonal degeneration and neuronal loss [<xref ref-type="bibr" rid="scirp.29484-ref33">33</xref>]. Besides visible lesions, also NAWM represents abnormal findings in MS. This may have an effect on the ratio between lesion and NAWM. These changes can be imaged with multiple MRI sequences. In this study, we imaged 80 patients diagnosed with CIS and three different subtypes of the neuroinflammatory disease MS. Lesion contrast were associated with various clinical data. This is an on-going study that will have four years of follow-up.</p><p>Different MRI sequences, such as T<sub>1</sub>- and T<sub>2</sub>-weighted SE, MT-prepared imaging, and DWI, can be used for the diagnosis of MS. T<sub>1</sub> is prolonged due to demyelination, inflammation, gliosis, edema, and axonal and neuronal loss and is, therefore, sensitive but not specific [<xref ref-type="bibr" rid="scirp.29484-ref34">34</xref>]. Its capacity to detect MS lesions is good [<xref ref-type="bibr" rid="scirp.29484-ref35">35</xref>] although even more lesions can be detected using T<sub>2</sub>-weighted images. There is large variation within the appearance of remyelinating lesions in T<sub>1</sub>-weighted images where hypointensity is stronger in demyelinated than in remyelinated lesions [<xref ref-type="bibr" rid="scirp.29484-ref28">28</xref>]. T<sub>1</sub> contrast does not correlate with demyelination [<xref ref-type="bibr" rid="scirp.29484-ref27">27</xref>]; however, both T<sub>1</sub> contrast [28-30] and MTR [<xref ref-type="bibr" rid="scirp.29484-ref30">30</xref>] of lesions have been shown to correlate with axonal density in post-mortem tissues. Magnetization transfer depends on interactions of water with myelin and, as a result, the image reflects myelin content. T<sub>2</sub>- weighted images, though sensitive to detecting MS lesions, are also non-specific in lesion characterization, except in the early stages [28,36]. With its short component (&lt;30 ms), T<sub>2</sub> reflects the myelin density of MS lesions [37,38]. DWI is sensitive in detecting lesions where myelin destruction has led to increased apparent diffusion coefficient (ADC) and decreased fractional anisotropy (FA). However, this method lacks specificity because it reflects each demyelination, gliosis, inflammation, axonal contraction, and axonal loss [<xref ref-type="bibr" rid="scirp.29484-ref39">39</xref>]. Therefore, MS lesions on MRI are non-specific, and furthermore, not biopsy-proven. This is a known but acceptable drawback of the McDonald criteria [1-3].</p><p>Three earlier studies [28-30] have thoroughly investigated the lesion contrast of several lesions in each patient. Therefore it might be argued whether selecting only two lesions, though the best distinguishable, in each patient is sufficient for a reliable analysis. However, due to the fact that no active lesions were present, we hypothesized that these were sufficient for describing the state of the disease. These lesions were large representative lesions, selected by the same reader over a short time period to be consistent. Furthermore, in several patients it would have been difficult to find more suitable lesions because they either had so few lesions that were seen in all sequences, or, they had so many lesions that finding a healthy comparison in the contralateral hemisphere was difficult. Therefore, for consistency exactly two representative lesions were selected in all patients. Furthermore, the lesion contrast was correlated with the total lesion volume. Therefore the hypothesis that the lesion contrast may represent the disease burden of the whole brain is justified and this hypothesis was tested in this work. Evaluation of active plaques could have increased the value of this study. However, the recruited patients did not have active phases at the time of the study.</p><p>In an earlier study with DWI, MS lesions have been suggested to be more intense in SPMS than RRMS [<xref ref-type="bibr" rid="scirp.29484-ref40">40</xref>]. However, another study on ADC has not been able to differentiate between RRMS, SPMS, and PPMS [<xref ref-type="bibr" rid="scirp.29484-ref41">41</xref>]. The patients in both earlier studies had somewhat [<xref ref-type="bibr" rid="scirp.29484-ref40">40</xref>] or considerably [<xref ref-type="bibr" rid="scirp.29484-ref41">41</xref>] higher EDSS scores than our patient cohort. This may well explain the inability of ADC to differentiate between subgroups in another study with high EDSS scores [<xref ref-type="bibr" rid="scirp.29484-ref41">41</xref>].</p><p>No correlation has previously been found between EDSS score and MTR in SPMS [<xref ref-type="bibr" rid="scirp.29484-ref11">11</xref>] or RRMS [<xref ref-type="bibr" rid="scirp.29484-ref42">42</xref>]; although in RRMS this is controversial [<xref ref-type="bibr" rid="scirp.29484-ref10">10</xref>]. Our results confirm previously described data, as we only found significant correlations in the total patient population consisting of four disease subgroups but not within any single subgroup in the case of MT-prepared T<sub>1</sub>-weighted images. Mean lesion T<sub>1</sub> has been shown to correlate with EDSS score in T<sub>1</sub> hypointense lesions, but not in T<sub>2</sub> lesions, in a cohort of RRMS and SPMS patients [<xref ref-type="bibr" rid="scirp.29484-ref43">43</xref>]. In our study, we found a similar correlation between EDSS score and decreased T<sub>1</sub> signal intensity, i.e., prolonged T<sub>1</sub>. Similar results of T<sub>1</sub> contrast (independent of contrast agent use) confirm the exclusion of contrast-enhancing lesions in our study. In contrast to both MT-prepared and non-prepared T<sub>1</sub>-weighted images, we found a negative correlation between EDSS score and FLAIR lesion contrast in RRMS patients. This suggests that in RRMS, myelin destruction may not increase with worsening EDSS score, perhaps due to myelin recovery between attacks. However, FLAIR is not specific to myelin content, as are DWI and T<sub>1</sub>-weighted SE with MT preparation, and this preliminary result should not lead to major conclusions.</p><p>Few studies have correlated MRI parameters with patient age in MS. Recently, though, negative correlation between lesion MTR and disease duration has been found in RRMS [<xref ref-type="bibr" rid="scirp.29484-ref42">42</xref>]. Also, T<sub>2</sub> lesion volume has been associated with age at onset and disease duration [<xref ref-type="bibr" rid="scirp.29484-ref44">44</xref>]. In our study of CIS patients, increased lesion contrast tended to correlate with patient age in several sequences, especially in the cerebral hemispheres. Plaques showed more intensity in older patients at onset. This is probably because the demyelination process occurs faster compared to younger patients [<xref ref-type="bibr" rid="scirp.29484-ref45">45</xref>]. In PPMS, the negative correlation between the signal intensity changes and age may be explained by the very different disease process compared to RRMS. This could mean either less inflammatory activity or more NAWM lesions in older patients.</p><p>In conclusion, contrast measurements seem to be limited in a daily radiological and clinical diagnosis in MS disease in reference to gaining information about disease course and activity, disease severity, and therapeutic responses. However, at higher fields MRI analyses used in this study might prove helpful when differentiating MS subgroups thus enabling earlier treatment of MS disease.</p></sec><sec id="s5"><title>5. ACKNOWLEDGEMENTS</title><p>This study was supported by the Alfred Kordelin foundation, Competitive Research Funding of the Pirkanmaa Hospital District and the Academy of Finland.</p><p><img src="3-9101577.files/image003.gif" /> <img src="3-9101577.files/image004.gif" /></p></sec><sec id="s6"><title>REFERENCES</title></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.29484-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">McDonald, W.I., Compston, A., Edan, G., et al. (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 50, 121-127. 
doi:10.1002/ana.1032</mixed-citation></ref><ref id="scirp.29484-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Polman, C.H., Reingold, S.C., Edan, G., et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Annals of Neurology, 58, 840-846. doi:10.1002/ana.20703</mixed-citation></ref><ref id="scirp.29484-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Polman, C.H., Reingold, S.C., Banwell, B., et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69, 292- 302. doi:10.1002/ana.22366</mixed-citation></ref><ref id="scirp.29484-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Miller, D., Barkhof, F., Montalban, X., et al. (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. The Lancet Neurology, 4, 281-288. 
doi:10.1016/S1474-4422(05)70071-5</mixed-citation></ref><ref id="scirp.29484-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sicotte, N.L., Voskuhl, R.R., Bouvier, S., et al. (2003) Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Investigative Radiology, 38, 423-427.  
doi:10.1097/01.RLI.0000065426.07178.f1</mixed-citation></ref><ref id="scirp.29484-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Stankiewicz, J.M., Glanz, B.I., Healy, B.C., et al. (2011) Brain MRI lesion load at 1.5 T and 3 T versus clinical status in multiple sclerosis. Journal of Neuroimaging, 21, e50-e56. doi:10.1111/j.1552-6569.2009.00449.x</mixed-citation></ref><ref id="scirp.29484-ref7"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mugler</surname><given-names> J.P. III and Brookeman</given-names></name>,<name name-style="western"><surname> J.R. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE)</article-title><source> Magnetic Resonanace in Medicine</source><volume> 15</volume>,<fpage> 152</fpage>-<lpage>157</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Miller, D.H., Grossman, R.I., Reingold, S.C., et al. (1998) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain, 121, 3-24. 
doi:10.1093/brain/121.1.3</mixed-citation></ref><ref id="scirp.29484-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names> P.W.</given-names></name>,<name name-style="western"><surname> Grant</surname><given-names> P.E. and Gonzalez</given-names></name>,<name name-style="western"><surname> R.G. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>Diffusion-weighted MR imaging of the brain</article-title><source> Radiology</source><volume> 217</volume>,<fpage> 331</fpage>-<lpage>345</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bellmann-Strobl, J., Stiepani, H., Wuerfel, J., et al. (2009) MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: A combined cross-sectional and longitudinal study. European Radiology, 19, 2066-2074. doi:10.1007/s00330-009-1364-z</mixed-citation></ref><ref id="scirp.29484-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hayton, T., Furby, J., Smith, K.J., et al. (2009) Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. Journal of Neurology, 256, 427-435. 
doi:10.1007/s00415-009-0110-4</mixed-citation></ref><ref id="scirp.29484-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Drayer, B., Burger, P., Hurwitz, B., et al. (1987) Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: Increased iron content? American Journal of Roentgenology, 149, 357-363. 
doi:10.2214/ajr.149.2.357</mixed-citation></ref><ref id="scirp.29484-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brass</surname><given-names> S.D.</given-names></name>,<name name-style="western"><surname> Chen</surname><given-names> N.K.</given-names></name>,<name name-style="western"><surname> Mulkern</surname><given-names> R.V.</given-names></name>,<name name-style="western"><surname> et al. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>Magnetic resonance imaging of iron deposition in neurological disorders</article-title><source> Topics in Magnetic Resonanace Imaging</source><volume> 17</volume>,<fpage> 31</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Khalil, M., Enzinger, C., Langkammer, C., et al. (2009) Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Multiple Sclerosis, 15, 1048-1054. doi:10.1177/1352458509106609</mixed-citation></ref><ref id="scirp.29484-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Neema, M., Arora, A., Healy, B.C., et al. (2009) Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. Journal of Neuroimaging, 19, 3-8.  
doi:10.1111/j.1552-6569.2008.00296.x</mixed-citation></ref><ref id="scirp.29484-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ceccarelli, A., Rocca, M.A., Neema, M., et al. (2010) Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Multiple Sclerosis, 16, 39-44.  
doi:10.1177/1352458509350310</mixed-citation></ref><ref id="scirp.29484-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Haacke, E.M., Makki, M., Ge, Y., et al. (2009) Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. Journal of Magnetic Resonance Imaging, 29, 537-544. doi:10.1002/jmri.21676</mixed-citation></ref><ref id="scirp.29484-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mittal, S., Wu, Z., Neelavalli, J., et al. (2009) Susceptibility-weighted imaging: Technical aspects and clinical applications, part 2. American Journal of Neuroradiology, 30, 232-252. doi:10.3174/ajnr.A1461</mixed-citation></ref><ref id="scirp.29484-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Dastidar, P., Heinonen, T., Lehtimiki, T., et al. (1999) Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. Journal of the Neurological Sciences, 165, 36- 42. doi:10.1016/S0022-510X(99)00071-4</mixed-citation></ref><ref id="scirp.29484-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ukkonen, M., Dastidar, P., Heinonen, T., et al. (2003) Volumetric quantitation by MRI in primary progressive multiple sclerosis: Volumes of plaques and atrophy correlated with neurological disability. European Journal of Neurology, 10, 663-669.  
doi:10.1046/j.1468-1331.2003.00617.x</mixed-citation></ref><ref id="scirp.29484-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ukkonen, M., Elovaara, I., Dastidar, P., et al. (2004) Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. Acta Neurologica Scandinavica, 109, 100-105. 
doi:10.1034/j.1600-0404.2003.00184.x</mixed-citation></ref><ref id="scirp.29484-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Taylor, I., Butzkueven, H., Litewka, L., et al. (2004) Serial MRI in multiple sclerosis: A prospective pilot study of lesion load, whole brain volume and thalamic atrophy. Journal of Clinical Neuroscience, 11, 153-158.  
doi:10.1016/S0967-5868(03)00145-0</mixed-citation></ref><ref id="scirp.29484-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Mowry, E.M., Beheshtian, A., Waubant, E., et al. (2009) Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology, 72, 1760-1765. doi:10.1212/WNL.0b013e3181a609f8</mixed-citation></ref><ref id="scirp.29484-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Bakshi, R., Neema, M., Healy, B.C., et al. (2008) Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Archives of Neurology, 65, 1449-1453.  
doi:10.1001/archneur.65.11.1449</mixed-citation></ref><ref id="scirp.29484-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Heinonen, T., Dastidar, P., Kauppinen, P., et al. (1998) Semi-automatic tool for segmentation and volumetric analysis of medical images. Medical &amp; Biological Engineering &amp; Computing, 36, 291-296.  
doi:10.1007/BF02522473</mixed-citation></ref><ref id="scirp.29484-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Bermel, R.A., Sharma, J., Tjoa, C.W., et al. (2003) A semiautomated measure of whole-brain atrophy in multiple sclerosis. Journal of Neurological Sciences, 208, 57- 65. doi:10.1016/S0022-510X(02)00425-2</mixed-citation></ref><ref id="scirp.29484-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Brady, M. and Smith, S. (2001) Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Transactions of Medical Imaging, 20, 45-57. 
doi:10.1109/42.906424</mixed-citation></ref><ref id="scirp.29484-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Brück, W., Bitsch, A., Kolenda, H., et al. (1997) Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Annals of Neurology, 42, 783-793.  
doi:10.1002/ana.410420515</mixed-citation></ref><ref id="scirp.29484-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">van Walderveen, M.A., Kamphorst, W., Scheltens, P., et al. (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology, 50, 1282-1288. doi:10.1212/WNL.50.5.1282</mixed-citation></ref><ref id="scirp.29484-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">van Waesberghe, J.H., Kamphorst, W., De Groot, C.J., et al. (1999) Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Annals of Neurology, 46, 747-754. 
doi:10.1002/1531-8249(199911)46:5&lt;747::AID-ANA10&gt;3.0.CO;2-4</mixed-citation></ref><ref id="scirp.29484-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Heinonen, T., Dastidar, P., Eskola, H., et al. (1998) Applicability of semi-automatic segmentation for volumetric analysis of brain lesions. Journal of Medical Engineering &amp; Technology, 22, 173-178.  
doi:10.3109/03091909809032536</mixed-citation></ref><ref id="scirp.29484-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dastidar, P., Heinonen, T., Vahvelainen, T., et al. (1999) Computerised volumetric analysis of lesions in multiple sclerosis using new semi-automatic segmentation software. Medical &amp; Biological Engineering &amp; Computing, 37, 104-107. doi:10.1007/BF02513274</mixed-citation></ref><ref id="scirp.29484-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Lassmann. H. (1999) The pathology of multiple sclerosis and its evolution. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences, 354, 1635-1640. doi:10.1098/rstb.1999.0508</mixed-citation></ref><ref id="scirp.29484-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Filippi, M., Yousry, T., Horsfield, M.A., et al. (1996) A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. Annals of Neurology, 40, 901-907. 
doi:10.1002/ana.410400612</mixed-citation></ref><ref id="scirp.29484-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Neema, M., Stankiewicz, J., Arora, A., et al. (2007) T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. Journal of Neuroimaging, 17, 16-21. 
doi:10.1111/j.1552-6569.2007.00131.x</mixed-citation></ref><ref id="scirp.29484-ref36"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tas</surname><given-names> M.W.</given-names></name>,<name name-style="western"><surname> Barkhol</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> van Walderveen</surname><given-names> M.A.</given-names></name>,<name name-style="western"><surname> et al. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1995</year>)<article-title>The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis</article-title><source> American Journal of Neuroradiology</source><volume> 16</volume>,<fpage> 259</fpage>-<lpage>264</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Moore, G.R., Leung, E., MacKay, A.L., et al. (2000) A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology, 55, 1506-1510. doi:10.1212/WNL.55.10.1506</mixed-citation></ref><ref id="scirp.29484-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Laule, C., Leung, E., Lis, D.K., et al. (2006) Myelin water imaging in multiple sclerosis: Quantitative correlations with histopathology. Multiple Sclerosis, 12, 747-753. 
doi:10.1177/1352458506070928</mixed-citation></ref><ref id="scirp.29484-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Rovira, A. and León, A. (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. European Journal of Radiology, 67, 409-414.  
doi:10.1016/j.ejrad.2008.02.044</mixed-citation></ref><ref id="scirp.29484-ref40"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Phuttharak</surname><given-names> W.</given-names></name>,<name name-style="western"><surname> Galassi</surname><given-names> W.</given-names></name>,<name name-style="western"><surname> Laopaiboon</surname><given-names> V.</given-names></name>,<name name-style="western"><surname> et al. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>ADC measurements in various patterns of multiple sclerosis lesions</article-title><source> Journal of the Medical Association of Thailand</source><volume> 89</volume>,<fpage> 196</fpage>-<lpage>204</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref41"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Droogan</surname><given-names> A.G.</given-names></name>,<name name-style="western"><surname> Clark</surname><given-names> C.A.</given-names></name>,<name name-style="western"><surname> Werring</surname><given-names> D.J.</given-names></name>,<name name-style="western"><surname> et al. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging</article-title><source> Magnetic Resonanace Imaging</source><volume> 17</volume>,<fpage> 653</fpage>-<lpage>661</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.29484-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Mesaros, S., Rocca, M., Sormani, M., et al. (2010) Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: A 14-month, multicentre, follow-up study. Multiple Sclerosis, 16, 325-331. doi:10.1177/1352458509358713</mixed-citation></ref><ref id="scirp.29484-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Parry, A., Clare, S., Jenkinson, M., et al. (2002) White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. Journal of Neurology, 249, 1279-1286. 
doi:10.1007/s00415-002-0837-7</mixed-citation></ref><ref id="scirp.29484-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Sormani, M.P., Rovaris, M., Comi, G., et al. (2009) A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology, 73, 1538-1542. doi:10.1212/WNL.0b013e3181c06679</mixed-citation></ref><ref id="scirp.29484-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Trojano, M., Liguori, M., Bosco Zimatore, G., et al. (2002) Age-related disability in multiple sclerosis. Annals of Neurology, 51, 475-480. doi:10.1002/ana.10147</mixed-citation></ref></ref-list></back></article>